Glaxo Receives France’s First Predatory Pricing Fine

Law360, New York (March 14, 2007, 12:00 AM EDT) -- France’s competition regulator has penalized GlaxoSmithKline PLC $13.2 million, the country’s first fine for predatory pricing, for allegedly pricing an injectable antibiotic below costs to prevent generics makers from entering the market.

The Conseil de la Concurrence ruled Wednesday that Glaxo Wellcome France, now known as GlaxoSmithKline France, sold injectable Zinnat (cefuroxime sodium) at below-market prices in 1999 and 2000 to eliminate competition from generics manufacturer Flavelab laboratories. Zinnat is an antibiotic commonly used in hospitals before operations.

Once Flavelab was out of the market, Glaxo...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.